$51.10+1.40 (+2.82%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Travere Therapeutics (TVTX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
8 figures withheld by our checks. Each blank figure names its reason.
Business engineGrowing fast: revenue compounds ~38.9%/yr (FY21→FY25), net margin −5.2%. Worth your attention in FY25: Share count (+49.1%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲110.5%
490.7
FY21→FY25CAGR +38.9%/yr
Net income ($M)▲92.1%
−25.5
FY21→FY25CAGR —
Free cash flow ($M)—
—
no FY25 valueCAGR —
Diluted EPS▲92.9%
−0.29
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+49.1%
59.8mn → 89.2mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-5¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 97.1% → 97.9%. Net margin -5.2% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 651,034.0 | 490,728.0 | 233,175.0 | 145,238.0 | 109,460.0 | 131,836.0 | ▲110.5% | +38.9% |
Cost of revenue | 9,545.0 | 10,339.0 | 7,744.0 | 11,450.0 | 4,420.0 | 3,818.0 | ▲33.5% | +28.3% |
Gross profit | 641,489.0 | 480,389.0 | 225,431.0 | 133,788.0 | 105,040.0 | 128,018.0 | ▲113.1% | +39.2% |
Research & development | 358,666.0 | 206,011.0 | 282,701.0 | 244,990.0 | 227,333.0 | 201,159.0 | ▼27.1% | +0.6% |
Selling, general & admin | 417,942.0 | 337,202.0 | 264,119.0 | 265,542.0 | 197,520.0 | 126,284.0 | ▲27.7% | +27.8% |
Total operating expenses | 774,986.0 | 543,213.0 | 549,258.0 | 521,926.0 | 424,853.0 | 327,443.0 | ▼1.1% | +13.5% |
Operating incomefeeds ROC rank | −133,497.0 | −62,824.0 | −323,827.0 | −388,138.0 | −319,813.0 | −199,425.0 | ▲80.6% | — |
Other income, net | −26,223.0 | 13,551.0 | 3,317.0 | 12,028.0 | −11,342.0 | −17,458.0 | — | — |
Pretax income | −159,720.0 | −49,273.0 | −320,510.0 | −376,110.0 | −331,155.0 | −216,883.0 | ▲84.6% | — |
Income tax | −5,298.0 | 988.0 | 120.0 | 223.0 | 313.0 | 409.0 | ▲723.3% | +24.7% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −121,507.0 | −25,546.0 | −321,545.0 | −111,399.0 | −278,482.0 | −180,091.0 | ▲92.1% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −1.28 | −0.29 | −4.08 | −1.50 | −4.37 | −3.01 | ▲92.9% | — |
Diluted shares (mn) | 94.63 | 89.21 | 78.89 | 74.27 | 63.76 | 59.83 | ▲13.1% | +10.5% |
| Margins | ||||||||
Gross margin96th pct in Healthcare | 98.5% | 97.9% | 96.7% | 92.1% | 96.0% | 97.1% | ▲1.2pp | +0.8pp |
Operating margin | −20.5% | −12.8% | −138.9% | −267.2% | −292.2% | −151.3% | ▲126.1pp | +138.5pp |
Net margin22nd pct in Healthcare | −18.7% | −5.2% | −137.9% | −76.7% | −254.4% | −136.6% | ▲132.7pp | +131.4pp |
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium, and 10 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-19 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Travere Therapeutics' revenue last fiscal year?
Travere Therapeutics reported revenue of $490.7M in fiscal 2025, up 110.5% from fiscal 2024.
What was Travere Therapeutics' net income?
Travere Therapeutics reported net income of −$25.5M in fiscal 2025, a net margin of −5.2%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

